129 related articles for article (PubMed ID: 26031897)
1. Bioregulation.
Pardee AB
J Cell Physiol; 2015 Dec; 230(12):2898-902. PubMed ID: 26031897
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethal vulnerabilities of cancer.
Fece de la Cruz F; Gapp BV; Nijman SM
Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
[TBL] [Abstract][Full Text] [Related]
3. Cancer epigenetics as biomarkers of clinical significance.
Panayiotidis MI
Cancer Lett; 2014 Jan; 342(2):168-9. PubMed ID: 24183850
[No Abstract] [Full Text] [Related]
4. [Pdcd4 tumor suppressor: properties, functions, and their application to oncology].
Vikhreva PN; Shepelev MV; Korobko EV; Korobko IV
Mol Gen Mikrobiol Virusol; 2010; (2):3-11. PubMed ID: 20545042
[TBL] [Abstract][Full Text] [Related]
5. Noncoding RNAs in molecular characterization of cancer preneoplasia.
Wang W; Srivastava S
Cancer Biomark; 2010; 9(1-6):133-40. PubMed ID: 22112473
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cells and markers: new model of tumorigenesis with therapeutic implications.
Natarajan TG; Ganesan N; Fitzgerald KT
Cancer Biomark; 2010; 9(1-6):65-99. PubMed ID: 22112470
[TBL] [Abstract][Full Text] [Related]
7. The changing face of tumor phenotypes.
Macfarlane R; Sauter ER
Biomark Med; 2012 Oct; 6(5):563-6. PubMed ID: 23075235
[No Abstract] [Full Text] [Related]
8. [Problems of tumor progression: doubts or hopes at the turn of the Millennium?].
Tímár J
Orv Hetil; 2000 Apr; 141(17):891-9. PubMed ID: 10827469
[TBL] [Abstract][Full Text] [Related]
9. Strategies used in the clinical trials of gene therapy for cancer.
Ajith TA
J Exp Ther Oncol; 2015; 11(1):33-9. PubMed ID: 26259388
[TBL] [Abstract][Full Text] [Related]
10. [Models of oncogenesis: an endless world?].
Larsen CJ
Bull Cancer; 2013 Jun; 100(6):555-60. PubMed ID: 23719507
[TBL] [Abstract][Full Text] [Related]
11. miR-214: a potential biomarker and therapeutic for different cancers.
Sharma T; Hamilton R; Mandal CC
Future Oncol; 2015; 11(2):349-63. PubMed ID: 25591843
[TBL] [Abstract][Full Text] [Related]
12. [MicroRNA and cancer].
Kiselev FL
Mol Biol (Mosk); 2014; 48(2):232-42. PubMed ID: 25850292
[TBL] [Abstract][Full Text] [Related]
13. Emerging approaches to target tumor metabolism.
Ross SJ; Critchlow SE
Curr Opin Pharmacol; 2014 Aug; 17():22-9. PubMed ID: 25048629
[TBL] [Abstract][Full Text] [Related]
14. Understanding genomic alterations in cancer genomes using an integrative network approach.
Wang E
Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571
[TBL] [Abstract][Full Text] [Related]
15. Engrailed homeobox transcription factors as potential markers and targets in cancer.
McGrath SE; Michael A; Pandha H; Morgan R
FEBS Lett; 2013 Mar; 587(6):549-54. PubMed ID: 23395604
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs in cancer: biomarkers, functions and therapy.
Hayes J; Peruzzi PP; Lawler S
Trends Mol Med; 2014 Aug; 20(8):460-9. PubMed ID: 25027972
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cells: a step toward the cure.
Boman BM; Wicha MS
J Clin Oncol; 2008 Jun; 26(17):2795-9. PubMed ID: 18539956
[No Abstract] [Full Text] [Related]
18. Roles of microRNAs in cancers and development.
Takasaki S
Methods Mol Biol; 2015; 1218():375-413. PubMed ID: 25319665
[TBL] [Abstract][Full Text] [Related]
19. Biology of Krüppel-like factor 6 transcriptional regulator in cell life and death.
Andreoli V; Gehrau RC; Bocco JL
IUBMB Life; 2010 Dec; 62(12):896-905. PubMed ID: 21154818
[TBL] [Abstract][Full Text] [Related]
20. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
